Most material SEC filings — September 2, 2026

On September 1, 2026, Advent International submitted a non-binding indication of interest to acquire all outstanding Class A common stock and Definitive OpCo Units not owned by Advent or founder Jason Krantz at $1.02 per share/unit in an all-cash transaction. The Special Committee of independent directors will evaluate the proposal with advisors (Rothschild Co and Skadden as counsel); no decisions have been made and no assurance exists that a transaction will be consummated.

ARC Group Acquisition I Corp. (a blank-check SPAC with ~$122.6M in assets) filed an 8-K on 2026-09-02 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, with a transfer of listing noted. The filing provides no specific details on which listing rule was violated, the timeline for delisting, or any remedial actions. This indicates the company has failed to meet Nasdaq or NYSE continued listing requirements.

On August 27, 2026, IRIDEX Corp. received notice from its listing exchange regarding failure to satisfy continued listing standards. The filing does not specify which exchange, which standards were violated, or what remedial actions are required. This is a critical corporate governance event for a company with a public market value of approximately $14.2M.

Corvex, Inc. (market cap ~$5.3M) executed a Securities Purchase Agreement dated August 31, 2026, with Goldman Sachs, Morgan Stanley, and Oppenheimer as placement agents to issue 4.258 million shares of common stock and Series D Preferred Stock at $7.75/share, raising approximately $33 million gross proceeds. The company will use proceeds to expand critical IT power capacity from 1.5 MW to 8 MW by end-2026, with a right of first refusal for an additional 12.5 MW, potentially reaching 20+ MW total. Closing expected September 2, 2026, subject to customary conditions.

VenHub Global (total assets ~$8.1M) entered into an Equity Purchase Agreement dated August 26, 2026 with Euphoria Capital, a Cayman Islands investment fund. The agreement permits VenHub to sell up to $100,000,000 of common stock to Euphoria Capital via 'puts' (company-directed sales at 97% of 3-day VWAP). VenHub immediately issued 800,000 commitment shares to Euphoria Capital as consideration. The transaction is subject to shareholder approval for shares beyond 18.3M (the 'Exchange Cap') and includes registration rights requiring VenHub to file an effective registration statement within 90 days. The commitment period runs 24 months or until the $100M is drawn, whichever is earlier.

GoPro signed a merger agreement dated September 1, 2026 with Action Acquisitions LLC (Parent) and its subsidiary Starman Optical, Inc. Each GoPro shareholder will receive $1.14 per share in cash plus 0.1 shares of Surviving Corporation Common Stock. The transaction is subject to stockholder approval, antitrust clearance, and customary closing conditions. Midtown Equities LLC committed to fund the equity required for the deal.

LivePerson stockholders voted to approve the proposed acquisition by SoundHound AI, Inc. (NASDAQ: SOUN) at a Special Meeting held September 2, 2026. The transaction is expected to close on September 4, 2026, subject to customary closing conditions including a notes restructuring agreement. No specific deal valuation, exchange ratio, or share count details are disclosed in this announcement.

TEN Holdings, Inc. (public market value ~$4.8M) filed an 8-K on September 2, 2026, disclosing Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing) for the period ending August 28, 2026. The filing provides no specific details regarding which exchange issued the notice, the particular listing standard violated, timeline for remediation, or any remedial actions undertaken. No dollar amounts, share counts, or counterparty details are disclosed in the available filing text.

Triller Group Inc. received a notice of delisting or failure to satisfy continued listing standards as of August 27, 2026. The filing indicates a transfer of listing is occurring. No specific financial amounts, counterparties, or remediation details are disclosed in this Form 8-K.

On August 27, 2026, Nasdaq notified Reborn Coffee that it violated Listing Rule 5250(c)(1) by failing to file its Q2 2026 Form 10-Q by the required deadline. The company has 60 days to submit a compliance plan; if accepted, Nasdaq may grant a 180-day extension (until February 16, 2027) to file the 10-Q. No immediate delisting occurs, but failure to cure within the extension period could trigger removal from Nasdaq. The filing also discloses that the company's auditors have issued a going-concern warning in the audit report for the year ended December 31, 2025.

cbdMD, Inc. (market cap ~$2.8M) entered a definitive asset purchase agreement on September 1, 2026, to acquire substantially all operating assets and brands of Twinlab Consolidated Holdings, Inc. through an assignment-for-benefit-of-creditors proceeding. Purchase price: $3,979,805 consisting of (a) assumption of $1.75M secured debt to Akretive Holdings at 9% annually, (b) issuance of 2,229,805 common shares (~19.9% of outstanding) valued at $1.00/share = $2,229,805, and (c) assumption of specified liabilities. The acquired brands include Twinlab, Reserveage, Metabolife, and Alvita Tea; combined trailing-twelve-month revenue (unaudited, through June 2026) approximately $30M, representing ~40% revenue increase for cbdMD. Transaction is subject to ABC court approval and customary closing conditions.

On September 1, 2026, Caring Brands (market cap ~$4.0M) completed an initial closing of $4.6M in convertible preferred shares from accredited investors under a $9M total private placement. An additional $4.4M in executed subscription documents awaits fund clearance (expected by September 4, 2026), which would trigger issuance of 4,400 Series B Preferred shares and warrants to purchase 8.8M common shares. Proceeds will fund domestic and international marketing campaigns and build an in-house sales force.

SRX Global Inc. (market cap ~$9.1M) has acquired senior secured debt from CERO Therapeutics Holdings, Inc. via a Consolidated Senior Secured Promissory Note dated August 27, 2026. Original principal: $5,666,108.77; maximum aggregate loan amount: $11,666,108.77 with up to $6,000,000 in additional advances. Interest accrues at 10% per annum (24.99% upon default); maturity October 15, 2026 (extendable 4×30 days). SRX is secured by CERo's T-cell therapy intellectual property (9 issued patents in US/Europe/Asia), all assets of CERo Therapeutics Inc. (subsidiary), and 100% equity pledge in CERo Therapeutics Inc. Holder may prepay only in connection with change of control; company must follow budget for advances.

Passage Bio, Inc. and Remix Therapeutics, Inc. executed an amended and restated merger agreement dated September 2, 2026 (amending the original June 24, 2026 agreement). The transaction contemplates a two-step merger in which Merger Sub merges with Remix (with Remix as surviving corporation), followed immediately by Remix merging into Merger Sub II. Key terms: Remix equity valued at $226M, Passage equity at $20M; concurrent financing of at least $99.929M; Remix shareholders to receive Remix Merger Shares calculated via allocation percentages tied to aggregate valuation; Passage Net Cash target of $5M (with deficiency/surplus adjustments); Remix Convertible Notes conversion, Remix Preferred Stock conversion, and assumption of Remix options/warrants all contemplated pre-closing. Both boards recommend approval; stockholder votes required from both parties.

On August 27, 2026, Alaska Industrial Development and Export Authority (AIDEA) authorized up to $25 million in funding for geotechnical drilling, permitting, hydrologic, and engineering work on the proposed West Susitna Access Project (WSAP), a 100.5-mile public/public-private road designed to connect U.S. GoldMining's Whistler Gold-Copper Project to Anchorage-area infrastructure. This authorization covers the 2026-2027 field seasons and is critical gating work for final road design, including bridge foundation work and alignment refinement. The company's Whistler project has a preliminary economic assessment modeling $2.0B NPV5% and 33% IRR at base case prices.

uniQure announced submission of a Biologics License Application (BLA) to the FDA for ifezuntirgene inilparvovec (AMT-130) for Huntington's disease treatment, supported by three-year Phase I/II data showing slowed disease progression. The company also submitted a Marketing Authorisation Application (MAA) to the U.K. MHRA and requested priority FDA review (potential 6-month review cycle). The product holds Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Fast Track designations from the FDA.

TScan announced a strategic reorganization: (1) pausing Phase 3 ALLOHA-2 enrollment for TSC-101 in heme malignancies due to insufficient capital after enrolling 7 patients on the treatment arm; (2) laying off ~75% of workforce; (3) shifting focus to in vivo-engineered TCR-T for solid tumors (PRAME and MAGE-A4 candidates entering IND-enabling studies with Phase 1 planned Q4 2027); (4) pursuing strategic partnerships for heme and autoimmune programs. The restructuring is expected to save $55M through end of 2027 and extend cash runway to Q4 2027. Updated Phase 1 ALLOHA data showed 100% (13/13) patients in Cohort C achieved complete donor chimerism with commercial-ready manufacturing.

G-III Apparel Group Ltd. and WHP Global completed the acquisition of Marc Jacobs brand from LVMH on September 1, 2026. The parties formed a 50-50 joint venture (MJ Topco, LLC) to co-own Marc Jacobs intellectual property, with WHP Global leading brand licensing and G-III operating the business (wholesale, retail, e-commerce). G-III targets $1 billion in long-term annual Marc Jacobs revenue; the deal is expected to be slightly dilutive in fiscal 2027 with accretion thereafter.

Edible Garden AG (market cap ~$7.7M) received formal notification from Nasdaq on September 2, 2026, confirming compliance with Listing Rule 5550(a)(2) requiring a minimum closing bid price of $1.00 per share. The company had been at risk of delisting; a Nasdaq Hearings Panel granted continued listing on July 27, 2026, conditioned on meeting this price threshold. The company now faces a one-year mandatory panel monitoring period through August 31, 2027; any future non-compliance would trigger automatic delisting without a cure period.

Rank One Computing (Nasdaq: ROC) completed its acquisition of Zuccaro Technical Consulting LLC (ZTC) on September 1, 2026. ZTC becomes a wholly owned ROC subsidiary, adding digital forensics engineering expertise, federal customer relationships, and incremental revenue. The deal expands ROC Evidence into end-to-end investigative intelligence and creates cross-selling opportunities across ROC's Vision AI portfolio. No purchase price, share count, earn-out structure, or financial metrics are disclosed in the filing.

Presidio Property Trust commenced an exchange offer on September 2, 2026, allowing holders of 973,736 outstanding shares of 9.375% Series D Cumulative Redeemable Perpetual Preferred Stock to exchange them for newly issued Common Stock at a ratio of 5.5 common shares per preferred share. The offer expires October 2, 2026, with no minimum tender requirement or financing conditions. Several directors and officers have indicated intent to participate on identical terms.

Digital Brands Group executed a binding contract for $3.3 million in guaranteed cash flow from September 1 through December 31, 2026, derived from only the first two markets of a larger $165 million U.S. Program spanning two years. The company expects guaranteed cash flow to increase significantly each quarter thereafter. This represents the initial tranche of a previously disclosed initiative announced July 27, 2026.

On September 1, 2026, NYSE notified Nerdy Inc. that it regained compliance with the minimum $1.00 share price requirement under NYSE Listed Company Manual Section 802.01C, based on closing price and 30-day average closing price as of August 31, 2026. The company had previously fallen below the threshold but recovered through stock price appreciation. Nerdy's Class A Common Stock continues listing on NYSE subject to other continued listing standards.

NetApp reported Q1 FY2027 net revenues of $2.025 billion (up 30% YoY from $1.559B), GAAP EPS of $1.88 (vs. $1.15), and non-GAAP EPS of $2.58 (vs. $1.55). All-flash array revenues hit record $1.3 billion (+47% YoY); Public Cloud revenues $206 million (+28% YoY). Company raised full-year FY2027 guidance to $7.975–$8.225B revenue and $9.73–$10.03 non-GAAP EPS. Acquired DataPelago Inc. for AI data infrastructure (~$78M in cash). Billings grew 36% to $2.057B; non-GAAP operating margin 31.9%.

HPE delivered Q3 FY2026 revenue of $12.2 billion (up 34% YoY), with GAAP operating profit up 464% and non-GAAP operating profit up 155% YoY. The company raised FY2026 revenue growth guidance to 34%-37% and raised FY2027 revenue growth guidance to 13%-17%. Free cash flow guidance for FY2026 raised to at least $3.75 billion, and FY2027 to at least $5.0 billion. Networking segment revenue grew 74.9% YoY to $2.9B; Cloud & AI grew 25.4% YoY to $9.0B.

Tilly's Inc. reported Q2 FY2026 (ended Aug 1, 2026) net income of $8.4M ($0.27/diluted share) vs. $3.2M ($0.10/share) prior year, on total net sales of $163.5M (+8.1% YoY) with comparable net sales up 12.1%. Gross profit improved 300 bps to 35.5% of sales. The company achieved its fifth consecutive quarter of year-over-year profit improvement and first profitable year-to-date period since 2022. For H1 FY2026, net income was $0.4M ($0.01/share) vs. net loss of $19.0M ($(0.63)/share) prior year on $288.2M sales (+11.3% YoY). Store count decreased from 232 to 220 stores; e-com sales grew 20.9% to $34.5M. Guidance provided for Q3 FY2026: net sales $150–155M with projected net income $2.2–3.7M ($0.07–0.12/share on ~32M diluted shares).

Scribe Therapeutics completed an upsized IPO on July 24, 2026, priced at $15/share, raising $155.5M gross proceeds (including Sanofi concurrent private placement). The company initiated first-in-human Phase 1 trial of STX-1150 in Australia (epigenetic silencing for LDL-C lowering) and secured $25.7M non-dilutive CIRM grants for STX-1200 (Lp(a)) and STX-1400 (triglycerides). Pro forma cash runway extends into H1 2029.

Snowflake reported Q2 FY2027 product revenue of $1.49B (+37% YoY) and total revenue of $1.55B (+35% YoY), with net revenue retention of 126%. The company raised full-year FY2027 product revenue guidance from $5.84B (31% growth) to $6.07B (36% growth) and increased non-GAAP operating margin guidance from 13.5% to 14.5%. Remaining performance obligations reached $9.0B (+30% YoY); customers with >$1M trailing 12-month product revenue: 828 (+27% YoY).

For Q2 FY2027 (ended July 31, 2026), Argan reported consolidated revenues of $383.976 billion, up 61.5% YoY from $237.743M, with net income of $53.3M (up 51% from $35.3M prior year) and diluted EPS of $3.76 vs. $2.50. Six-month revenue was $674.9M (up 56.5% YoY), net income $99.4M (+72% YoY), EPS $7.01 vs. $4.09. Gross margin expanded 70 bps to 19.3% (Q2) and 130 bps to 20.1% (6M). Power segment grew revenue 53% YoY to $301M at 22% gross margin. Cash position strengthened to $1.028B from $895M; project backlog $2.518B; company acquired ValCor Communications in Teledata segment; dividend raised to $0.50/share (from $0.375).

Hecate Energy LLC and EGH Acquisition Corp. announced resolution of lender-related legal matters and litigation that had delayed their previously announced business combination. The $1.2 billion pre-money enterprise value transaction, originally announced January 22, 2026, now expects to close in early Q1 2027 pending EGH shareholder approval. Hecate is also in discussions with potential interim investors for additional capital to support the de-SPAC process and balance sheet.

Senti Biosciences amended its Securities Purchase Agreement (dated April 27, 2026) to add NSG BioInnovation Fund, L.P. as a new investor purchasing $2,000,000 of Additional Notes. Combined with prior tranches, the Lead Investor (CPIF II-7 Limited) has committed $10,000,000 (May 20, 2026) plus $4,000,000 (August 14, 2026), while the new joining buyer commits $2,000,000 (Additional Closing Date set for September 4, 2026). Total potential funding under the agreement reaches $40,000,000 ($10M initial + $30M additional notes capacity). The amendment also confirms that completion of these purchases satisfies the Lead Investor's funding obligations under the July 14, 2026 Merger Agreement with Celadon Partners SPV 35 Limited.

Bank of Hope (Hope Bancorp subsidiary) has received all required regulatory approvals from the FDIC and California Department of Financial Protection and Innovation to acquire the Commercial Banking Unit of SMBC MANUBANK. The transaction is expected to close in Q4 2026. Additionally, Bank of Hope and SMBC entered into a collaboration agreement to provide banking services to SMBC's Japan-based customers in the US upon closing.

Helix Energy Solutions Group, Inc. changed its name to Hornbeck Offshore Services, Inc. on September 1, 2026. KPMG LLP, the company's principal accountant since February 26, 2026, was dismissed on September 2, 2026. KPMG's letter indicates they reported on consolidated financials for years ended December 31, 2025 and 2024, with discontinued operations noted.

VolitionRx secured a waiver and consent from Lind Global Asset Management XII LLC dated September 2, 2026, permitting unlimited sales under its ATM (at-the-market) offering agreement without triggering default or anti-dilution adjustments on $9.9M in convertible notes and warrants held by Lind. The company previously faced a $10M annual cap on ATM sales; this waiver removes that constraint and waives Lind's remedies for prior above-cap sales occurring before August 28, 2026. Conversion price fixed at $0.44 and warrant exercise price at $0.572.

On July 29, 2026, Accuray issued two separate warrant certificates: (1) TCW Rescue Financing Fund II LP received 7,987,743 warrants, and (2) TCW WV Financing LLC received 598,114 warrants. Both exercise at $0.01/share, expire July 29, 2033, and were issued as consideration for Amendment No. 3 to the Financing Agreement, which amended financial covenants and liquidity provisions. Total warrant shares: 8,585,857, representing ~9.9% of current market cap at face value.

Director Cheung Kong Yiu (NIVF) bought 3.7M shares (~$4.2M) on the open market (50% of holdings). Open-market insider purchase — historically a bullish signal.

Effective September 4, 2026, Thomas R. Szoke was appointed Interim CEO with base salary increased to $300,000/annum plus $10,000 signing bonus and conditional $210,000 bonus upon material corporate transaction closing. Rhoniel A. Daguro resigned as CEO (accepted for Good Reason) and was appointed Chairman; he receives health insurance stipend (12 months), conditional $400,000 bonus upon corporate transaction closing, 80,000 stock options at 2x current price, 20,000 warrant at $2.00/share (upon $10,000 payment), and pro-rated severance payable after corporate transaction closing. All payments subordinate to April 29, 2026 Senior Secured Debentures.

10% owner Empery Asset Management, LP (EMPD) bought 500K shares (~$1.8M) on the open market (9.2% of holdings). Open-market insider purchase — historically a bullish signal.

CHAIRMAN & CEO Williams Charles Alan (NPB) bought 85K shares (~$1.4M) on the open market (3.3% of holdings). Open-market insider purchase — historically a bullish signal.

Five Below reported Q2 FY2026 net sales of $1.26B (+22.9% YoY) with comp sales +14.1%; opened 52 net new stores to reach 2,022 locations; raised full-year net sales guidance to $5.63–5.71B (from $5.40–5.48B), comparable sales to +10–12% (from +6–8%), and diluted EPS to $12.10–12.58 (from $8.62–9.02). Board approved new $600M share repurchase program on August 29, 2026, replacing prior authorization. Q2 diluted EPS was $3.99 (GAAP) and $1.68 (adjusted); YTD net income $344.5M (+310% vs. prior year).

Attovia Therapeutics completed an upsized IPO on Nasdaq (ticker ATTO) raising $332.4 million gross proceeds ($305.4 million net), announced in August 2026. Lead candidate ATTO-1310 demonstrated preliminary clinical proof of concept in Phase 1b for chronic pruritus and high-itch atopic dermatitis, with complete data expected Q4 2026; Phase 2 studies planned H1 2027. Two additional programs (ATTO-2306, ATTO-1091) advancing toward Phase 1 initiation H1 2027. Cash runway extended to 2030.

Executive Chairman RADY ERNEST S (AAT) bought 167K shares (~$3.7M) on the open market (6.5% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner PAINE SCHWARTZ FOOD CHAIN FUND V GP, LTD. (SUJA) bought 525K shares (~$5.4M) on the open market (4.3% of holdings). Open-market insider purchase — historically a bullish signal.

10% owner ADAR1 Capital Management, LLC (TENX) bought 770K shares (~$1.4M) on the open market (12% of holdings). Open-market insider purchase — historically a bullish signal.

REX American Resources reported fiscal Q2 2026 net income of $34.9M ($1.06 diluted EPS on 33.09M shares) versus $7.1M ($0.22 EPS) in Q2 2025—a 391% increase in net income. Gross profit rose to $53.3M from $14.3M, driven by improved crush margins and $18.4M in Section 45Z production tax credits. On August 17, 2026, the EPA issued draft permits for three Class VI injection wells for REX's One Earth carbon capture project, with $191.2M invested to date in the expansion and CCS facility.

Wheeler Real Estate Investment Trust filed Form 8-K on September 2, 2026, reporting an unregistered sale of equity securities as of August 28, 2026 (Item 3.02). The filing provides no specific details: counterparties, dollar amounts, share counts, pricing, or terms are not disclosed in the accessible filing header or document index. The full details must be in the complete submission text, which is referenced but not reproduced here.

Matrix Service Company reported Q4 FY2026 (ended June 30, 2026) revenue of $244.5M (13% YoY growth), net income of $1.1M ($0.04 per share) versus prior-year loss of $11.3M, and adjusted net income of $4.6M ($0.16 per share). Full-year revenue was $873.6M versus $769.3M; adjusted net income was $7.4M ($0.26 per share) versus adjusted loss of $25.9M. Company ended with zero debt, $283.9M liquidity, and $953.2M backlog with $169M in Q4 awards including a major mining project. SG&A expenses fell to $16.9M from $17.6M, reflecting cost restructuring over 18 months.

Texas Ventures Acquisition III Corp (SPAC) agreed to merge with Plus Automation, Inc. dated September 2, 2026. Equity value set at $800,000,000. Plus Automation shareholders receive SPAC Common Stock at an Exchange Ratio based on Per Share Equity Value divided by $10.00. Up to 70,000,000 earnout shares issuable upon hitting stock price targets of $15, $18, and $21 over 5 years. SPAC to domesticate from Cayman Islands to Delaware prior to closing.